Medexus Pharmaceuticals Inc. (TSX: MDP)

Canada flag Canada · Delayed Price · Currency is CAD
1.820
0.00 (0.00%)
Jul 2, 2024, 3:53 PM EDT
-16.51%
Market Cap 44.51M
Revenue (ttm) 158.30M
Net Income (ttm) 8.04M
Shares Out 24.46M
EPS (ttm) 0.40
PE Ratio 4.55
Forward PE 14.53
Dividend n/a
Ex-Dividend Date n/a
Volume 20,181
Open 1.820
Previous Close 1.820
Day's Range n/a
52-Week Range 1.440 - 3.530
Beta 1.89
Analysts n/a
Price Target 2.94 (+61.54%)
Earnings Date Aug 6, 2024

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, a... [Read more]

Sector Healthcare
CEO Kenneth d'Entremont
Employees 82
Stock Exchange Toronto Stock Exchange
Ticker Symbol MDP
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.